18
total announcements
524558.BO · 15 min delayed
Neuland Laboratories Ltd
Neuland Laboratories Ltd has announced that Crisil Ratings has reaffirmed its credit rating as CRISIL A+/ Positive with a revised outlook to 'Positive' and CRISIL A1 for short-term rating.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has published a newspaper advertisement regarding the opening of a Special Window for transfer and dematerialization of physical shares, as per SEBI Circular No. HO/38/13/11(2)2026-MIRSD-PoD/I/3750/2026, in the Financial Express and Nava Telangana on August 22, 2026.
Neuland Laboratories Ltd
Malabar India Fund Ltd has disclosed selling 2,72,634 equity shares of Neuland Laboratories Ltd in the secondary market, resulting in a 2.12% stake reduction.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has informed that the US FDA has inspected its Unit 3 manufacturing facility and issued a Form 483 with one observation regarding procedural improvements in water and environmental monitoring.
Neuland Laboratories Ltd
Neuland Laboratories Ltd reported Q1FY27 earnings with a 16.3% revenue growth to INR650.1 crores, driven by commercial CMS projects. EBITDA margin improved to 35.5% and profit after tax stood at INR147.4 crores. Working capital efficiency improved with a reduction in working capital days from 137 to 84 days.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has announced a schedule of analyst/institutional investor meetings on August 12, 2026, at Emkay Confluence 2026 in Mumbai.
Neuland Laboratories Ltd
Neuland Laboratories Ltd published copies of newspaper advertisement regarding financial results for the quarter ended June 30, 2026, as per Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has made available the audio recording of its earnings call for the quarter ended June 30, 2026, conducted on August 5, 2026.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has announced the enhancement of its manufacturing capacity at Unit 1 located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana. The company will add 18 KL of capacity, with an investment of Rs. 39.8 crores, to be completed within 6-7 months. The company has also executed a corporate guarantee of Rs. 40 crores in favour of Gland Pharma Limited for a loan licence agreement to establish dedicated manufacturing capacity and incur capital expenditure for certain products.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has announced unaudited financial results for the quarter ended June 30, 2026, and has also approved the execution of a corporate guarantee of Rs. 40 crores in favour of Gland Pharma Limited, and enhancement of manufacturing capacity at Unit 1.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has announced its Q1FY27 financial results, with total income at Rs. 650.1 crore, EBITDA at Rs. 231.1 crore, and PAT at Rs. 147.4 crore, showing significant year-over-year growth. The company's working capital days of sale decreased to 84 days in Q1FY27 from 137 days in Q4FY26, and capex outflow was Rs. 122 Cr in Q1FY27.
Neuland Laboratories Ltd
Neuland Laboratories Ltd announced its financial results for the quarter ended June 30, 2026, with total income at Rs.650.1 crore, EBITDA at Rs.231.1 crore, and EPS at Rs.114.9.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has announced its unaudited financial results for the quarter ended June 30, 2026. The company has reported a corporate guarantee of Rs. 40 crores in favour of Gland Pharma Limited for establishing dedicated manufacturing capacity and incurring capital expenditure. Additionally, the company has enhanced its manufacturing capacity at Unit 1 located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has announced unaudited financial results for the quarter ended June 30, 2026, and approved a corporate guarantee of Rs. 40 crores in favour of Gland Pharma Limited for a loan licence agreement. The company also plans to enhance its manufacturing capacity at Unit 1 by 18 KL, with an investment of Rs. 39.8 crores.
Neuland Laboratories Ltd
Neuland Laboratories Ltd held its 42nd Annual General Meeting on August 4, 2026, through video conferencing. The meeting was attended by 81 members, and the requisite quorum was present. The company declared a final dividend of Rs. 34.00 per equity share, and appointed a new director. The meeting was conducted in accordance with the circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India.
Neuland Laboratories Ltd
Neuland Laboratories Ltd held its 42nd Annual General Meeting on August 4, 2026, through video conferencing, with 81 members attending. The meeting approved the audited financial statements, declared a final dividend of Rs. 34.00 per equity share, and appointed new directors.
Neuland Laboratories Ltd
Neuland Laboratories Ltd has commenced commercial production at two additional capacities under its expansion plans at Unit 1 and Unit 3 in Telangana, India.
Neuland Laboratories Ltd
Neuland Laboratories Ltd announces Q1FY27 Earnings Call details, inviting investors to a conference call on August 05, 2026, at 17:30 Hrs (IST). The company has been a leading manufacturer of APIs for over 4 decades, with cGMP certifications from various global authorities.